KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Aquestive Therapeutics (AQST) Other Gross PP&E Adjustments (2017 - 2026)

Aquestive Therapeutics has reported Other Gross PP&E Adjustments over the past 9 years, most recently at $40.3 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments changed 0.06% year-over-year to $40.3 million; the TTM value through Dec 2025 reached $40.3 million, changed 0.06%, while the annual FY2025 figure was $40.3 million, 0.06% changed from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $40.3 million at Aquestive Therapeutics, down from $41.7 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $43.4 million in Q3 2022 and troughed at $35.0 million in Q4 2022.
  • A 5-year average of $40.7 million and a median of $40.7 million in 2021 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: fell 13.45% in 2022 and later increased 13.53% in 2023.
  • Year by year, Other Gross PP&E Adjustments stood at $40.5 million in 2021, then decreased by 13.45% to $35.0 million in 2022, then rose by 13.53% to $39.8 million in 2023, then increased by 1.37% to $40.3 million in 2024, then rose by 0.06% to $40.3 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for AQST at $40.3 million in Q4 2025, $41.7 million in Q3 2025, and $39.5 million in Q2 2025.